Lilly Seeks Appeal of UK Ruling

Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowIndianapolis-based Eli Lilly and Co. (NYSE: LLY) says it plans to seek permission to appeal a United Kingdom High Court patent ruling that favors a competitor. The case involves Actavis PLC (NYSE: ACT) marketing a treatment in four European countries.
In a statement from Lilly, the company says the court decided the Alimta vitamin regimen patent "would not presently be infringed by Actavis marketing pemetrexed trometamol in the UK, France, Italy and Spain with instructions to dilute the product only with dextrose solution."
Alimta is a blockbuster cancer treatment from Eli Lilly. Its vitamin regimen patent are set to expire in June 2021.
Lilly General Council Michael Harrington says "we strongly disagree with the ruling by the UK High Court granting a declaration of non-infringement on the Alimta vitamin regimen patents under these circumstances. We plan to seek permission to appeal this ruling."
You can connect to more about the decision by clicking here.